Future Procurement Opportunity (FPO) – Supply of permanent coronary drug eluting stents under a market share arrangement

Details

RFx ID :	31681233
Tender Name :	Future Procurement Opportunity (FPO) – Supply of permanent coronary drug eluting stents under a market share arrangement
Reference # :	qA73751
Open Date :	Q2 2025
Indicative RFx Release Date  :	Q3 2025  [?]
Tender Type :	Future Procurement Opportunity (FPO)
Project Status :	Initial development  [?]
Indicative Total Value :	$10M - $25M  [?]
Expected number of contracts offered :	1
Tender Coverage :	Sole Agency  [?]
Categories :	42000000 - Medical Equipment and Accessories and Supplies
Regions:	New Zealand
Required Pre-qualifications :	None
Contact :	Pharmac Procurement Team procurement@Pharmac.govt.nz

Pharmac plans to issue a single-stage Request for Proposals (RFP) for the supply of permanent coronary drug-eluting stents under a market share arrangement. Currently, Pharmac has a market share arrangement with a single supplier for permanent coronary drug-eluting stents, with a minimum market share of 65% guaranteed under its agreement.

The approximate gross annual expenditure of all permanent coronary drug eluting stents in the 2023/2024 financial year was $6,124,000. Under the current market share Health New Zealand | Te Whatu Ora hospitals are expected to use the successful supplier for a minimum of 65% of their usage.

As part of the upcoming RFP process, Pharmac will seek expert advice from a range of a health care professionals, technical experts and consumers about the use of permanent coronary drug-eluting stents to inform this work.

Further detail and notification of approval for the current market share arrangement is available on Pharmac’s website.

• Permanent coronary drug eluting stents (https://www.pharmac.govt.nz/hospital-devices/whats-happening-in-each-category/permanent-coronary-drug-eluting-stents)